There is no single “normal” transcutaneous bilirubin (TcB) value for newborns. Instead, TcB readings are interpreted against hour-specific nomograms that plot bilirubin levels against the baby’s age in hours, because bilirubin rises naturally after birth and peaks around day three to five before declining. A reading of 8 mg/dL at 24 hours of life might sit comfortably in a low-risk zone, while the same number at six hours could signal trouble. This hour-by-hour framing makes TcB interpretation more nuanced than a simple “normal vs. abnormal” cutoff, and understanding how the numbers are read, where the device is placed, and when it can be trusted matters for every parent and clinician dealing with newborn jaundice.
How Transcutaneous Bilirubin Measurement Works
A TcB device is a handheld tool pressed gently against a newborn’s skin, usually on the forehead or sternum. It shines light into the skin and measures how much light is reflected back at different wavelengths. Because bilirubin absorbs light in a characteristic way, the device can estimate the bilirubin concentration in the skin’s tissue without drawing blood. The skin also contains melanin and hemoglobin, both of which absorb light at overlapping wavelengths, so the device’s internal algorithm has to separate bilirubin’s signal from these other pigments.1PubMed Central. Measuring and imaging of transcutaneous bilirubin, hemoglobin, and melanin based on diffuse reflectance spectroscopy That separation is imperfect, which is why TcB is treated as a screening tool rather than a definitive diagnosis. When a TcB value crosses into a concerning zone, the next step is a blood draw for total serum bilirubin (TSB), which remains the gold standard.
Hour-Specific Nomograms Instead of Fixed Cutoffs
The reason you will not find a single “normal range” for TcB is that bilirubin physiology changes rapidly in the first days of life. Nearly all healthy newborns experience a rise in bilirubin after birth as their bodies break down fetal red blood cells faster than the immature liver can process the waste. Researchers have charted this natural rise by measuring thousands of babies at known ages and plotting the results into percentile curves, creating what are called hour-specific nomograms.
The landmark approach in this area involved over 10,000 TcB measurements from more than 2,000 healthy term and near-term newborns, producing a predictive nomogram that assigns each baby to a risk zone based on where their TcB falls relative to age-matched percentiles.2Pediatrics. Transcutaneous Bilirubin Nomogram for Prediction of Significant Neonatal Hyperbilirubinemia Babies whose TcB tracks above the 95th percentile for their age are considered high risk and typically need a confirmatory blood test and close follow-up. Those tracking between roughly the 40th and 75th percentiles fall into an intermediate zone, while babies below the 40th percentile are at low risk for developing dangerous levels.
These nomograms have been developed in multiple populations. A study in Myanmar, for example, created smoothed percentile curves at the 2.5th, 50th, and 97.5th percentiles for the first 72 hours of life using over 3,000 data points from local newborns.3PubMed. Hour-specific nomogram for transcutaneous Bilirubin in newborns in Myanmar A separate Indian study of more than 1,000 neonates found that the rate of bilirubin rise was about 0.2 mg/dL per hour in the first 12 hours, slowing to 0.17 mg/dL per hour in the 12-to-24-hour window and declining further on the second day. Babies who eventually needed phototherapy had consistently higher TcB readings and a faster rate of rise in the first 48 hours. The practical takeaway is that a baby’s TcB number means almost nothing without knowing the baby’s age in hours and which percentile curve the reading falls on. Nomogram-based TcB tracking has also been shown to predict which babies will later need phototherapy, since infants whose readings sharply intersect higher percentile curves tend to require treatment.4PubMed Central. The use of transcutaneous bilirubin nomograms for the prevention of bilirubin neurotoxicity in the neonates
How Close Is TcB to the Blood Test
Because TcB is a screening estimate rather than a direct blood measurement, the question of how closely it tracks TSB matters a lot. The short answer is that TcB tends to slightly overestimate TSB in most newborns, which is actually a useful safety feature for screening: it means the device errs on the side of flagging babies who might need a blood draw rather than missing them. One study of term and preterm infants found the average difference between TSB and TcB was about −0.9 mg/dL, meaning TcB read roughly 1 to 2 mg/dL higher than the blood result.5PubMed Central. The Accuracy of Transcutaneous Bilirubin as a Screening Test in Preterm Infants That degree of overestimation is considered clinically acceptable because it keeps sensitivity high.
Larger studies confirm strong correlations between TcB and TSB, with values reported in the range of 0.87 to 0.90 depending on whether the reading is taken at the forehead or sternum.6PubMed Central. Correlation of microbilirubin with total serum bilirubin and transcutaneous bilirubin Screening performance at common treatment thresholds (above 10, 12, or 15 mg/dL) has shown sensitivity and specificity at or above 80%, with the area under the curve exceeding 0.9, meaning TcB reliably identifies babies who have crossed into concerning territory. Still, clinical guidelines consistently recommend confirming any borderline or elevated TcB with a blood draw before starting treatment.
One important caveat from a Cochrane review is that simple correlation coefficients between TcB and TSB are not the right way to evaluate whether TcB is a good diagnostic test. Sensitivity and specificity at specific treatment thresholds matter more, because a high correlation does not guarantee the device catches every baby who needs intervention.7Cochrane Database of Systematic Reviews. Transcutaneous bilirubin measurement for detecting hyperbilirubinaemia in newborns
Forehead Versus Sternum Readings
Where you place the device on the baby changes the number you get. Research has consistently found that sternal readings run higher than forehead readings, with one study reporting a mean difference of about 1 mg/dL.8PubMed. Comparison of Transcutaneous Bilirubin Measurements at the Forehead and Sternum in Neonates That same study found that sternal TcB correlated slightly more closely with TSB and had tighter limits of agreement, making it the preferred site for pre-treatment screening in outpatient settings.9PubMed. Which Is More Accurate: Transcutaneous Bilirubin Measurement on the Forehead or Sternum?
The picture flips, however, once a baby is receiving phototherapy. During treatment, the sternum is typically exposed to the therapeutic light, which bleaches bilirubin in the skin and causes the device to underestimate the true blood level more than it would on the forehead. A study of sick infants found that without phototherapy, both sites correlated well with TSB, but during phototherapy the forehead was a better match because it is often shielded by headgear or positioning.10PubMed Central. The forehead is a better site than the sternum to check transcutaneous bilirubin during phototherapy in sick infants The practical rule is straightforward: use the sternum before phototherapy, and switch to covered skin (often the forehead) during treatment.
TcB Accuracy During and After Phototherapy
Phototherapy creates a known challenge for TcB accuracy. The blue light used in treatment breaks down bilirubin in the skin faster than in the blood, so a TcB reading taken on light-exposed skin will underestimate the actual blood level. A meta-analysis across multiple studies found that TcB measured on covered (unexposed) skin maintains good agreement with TSB both before and during phototherapy, with limits of agreement staying within a safety margin of about 50 µmol/L (roughly 3 mg/dL). However, after phototherapy ends, TcB on covered skin tends to underestimate TSB more significantly, and on uncovered skin the underestimation is even worse.11Pediatrics. Transcutaneous Bilirubin Accuracy Before, During, and After Phototherapy: A Meta-Analysis
A separate study in a multiethnic population confirmed that certain TcB devices maintain acceptable accuracy during phototherapy (bias within about ±3.2 mg/dL) but found that some devices only correlate well with TSB again after 24 hours post-treatment.12PubMed Central. Transcutaneous bilirubin reliability during and after phototherapy depending on skin color For preterm infants, adding a buffer of about 50 µmol/L to the TcB reading at 70% of the phototherapy threshold could reduce blood draws by roughly 42% while keeping false negatives to about 2%.13PubMed Central. Should transcutaneous bilirubin be measured in preterm infants receiving phototherapy? That kind of adjusted protocol highlights how hospitals balance the desire to avoid unnecessary heel pricks against the need to catch genuinely high bilirubin levels.
How Skin Pigmentation Affects the Reading
Skin color is one of the most discussed confounders in TcB measurement. The device has to mathematically separate melanin’s light absorption from bilirubin’s, and that separation becomes harder as melanin concentration increases. An in vitro study that simulated varying levels of skin pigmentation found that higher melanin combined with higher bilirubin levels led to larger underestimations, ranging from about 1.5 to 7.7 mg/dL at a moderate bilirubin level.14PubMed Central. Skin color influences transcutaneous bilirubin measurements: a systematic in vitro evaluation That is a clinically meaningful error when treatment decisions hinge on whether a baby is above or below a threshold.
Interestingly, not all studies point in the same direction. A clinical study using a neonatal skin-color scale found that TcB tended to overestimate blood bilirubin to a greater degree in dark-skinned newborns, the opposite of what the in vitro data might predict.15PubMed. Reliability of transcutaneous bilirubin determination based on skin color determined by a neonatal skin color scale of our own The discrepancy likely reflects differences between controlled laboratory conditions and the complex, multi-layered skin of real babies. What both lines of evidence agree on is that skin pigmentation shifts TcB accuracy in ways that vary by device and population, so clinicians caring for babies with darker skin should have a lower threshold for confirming TcB with a blood test.
Differences Between TcB Devices
Not all transcutaneous bilirubinometers perform the same way. The two most widely studied devices globally are the Dräger Jaundice Meter (JM series) and the BiliChek by Philips Respironics. A head-to-head comparison found the JM-105 on the sternum had the best overall agreement with TSB, with a mean difference of just −0.21 mg/dL. However, accuracy differed across racial groups, and at higher bilirubin levels the correlation weakened.16PubMed. A Prospective Comparison of Transcutaneous and Serum Bilirubin Within Brief Time Intervals In about 5% of paired measurements, the JM-105 underestimated TSB by 2 mg/dL or more.
An earlier comparison between BiliChek and the JM-103 found that BiliChek tended to underestimate TSB (mean difference of −1.4 mg/dL), while JM-103 was closer to the blood value with a mean difference of 0.3 mg/dL. ROC analysis for a TSB threshold of 12 mg/dL showed the JM-103 outperformed BiliChek.17Clinical Biochemistry. Transcutaneous bilirubin measurement: Comparison of Respironics BiliCheck and JM-103 in a normal newborn population A three-device comparison on a multiracial population confirmed that both BiliChek and the JM-103 performed well, while the BiliMed device lagged behind, with a notably lower correlation coefficient.18PubMed Central. Measuring transcutaneous bilirubin: a comparative analysis of three devices on a multiracial population The practical implication is that the specific device your hospital uses matters, and clinicians should be familiar with the known bias direction of their equipment.
Screening Programs and What They Accomplish
Universal TcB screening at discharge has been adopted in many hospitals as a way to catch jaundice before it becomes dangerous. A Cochrane review found moderate-certainty evidence that TcB screening probably reduces hospital readmission for jaundice compared to visual inspection alone, with the screened group having roughly a quarter of the readmission rate.19Cochrane Database of Systematic Reviews. Transcutaneous bilirubin screening for jaundice in newborns A separate systematic review and meta-analysis of universal screening at discharge reported similar reductions in both readmission and severe hyperbilirubinemia, though the effect on rare outcomes like exchange transfusion and brain injury remained uncertain due to very small event numbers.20Journal of Global Health. Universal screening for hyperbilirubinemia in term healthy newborns at discharge: A systematic review and meta-analysis
Implementing universal TcB screening also changes how resources are used. One hospital found that after introducing routine TcB screening, overall phototherapy use dropped from 59 to 39 per 1,000 infants, likely because earlier identification allowed for better-targeted follow-up rather than precautionary treatment.21PubMed. Effect of universal neonatal transcutaneous bilirubin screening on blood draws for bilirubin analysis and phototherapy usage
TcB in Home and Community Settings
One of TcB’s biggest advantages is that it does not require a laboratory. That makes it especially useful for midwife-led home visits and community clinics where drawing blood is logistically difficult or stressful for families. A home-based screening program using TcB combined with telemedicine found that over 80% of potential hospital referrals could be safely avoided, while the device correctly identified every infant who actually needed phototherapy.22PubMed Central. Home-Based Transcutaneous Bilirubin Screening and Telemedicine Reduce Neonatal Referrals Agreement between a clinician’s visual assessment and TcB-based need for follow-up was strikingly poor, which underscores why eyeballing jaundice is unreliable.
A decision-analytical model from a midwifery-led home care setting in the Netherlands examined universal versus selective TcB screening for over 2,300 near-term and full-term neonates. Universal screening identified 21 additional cases of hyperbilirubinemia compared to visual inspection, at a savings of about €15 per baby, though it required more heel pricks for confirmatory blood tests. Selective screening of visually jaundiced babies reduced the extra blood draws without compromising diagnostic accuracy.23JAMA Network Open. Universal Transcutaneous Bilirubin Screening in a Midwifery-Led Home Care Setting
Cost Savings Compared to Blood Tests
The economics of TcB are favorable. A Canadian cost-minimization analysis found that implementing TcB-first screening reduced the need for blood draws by over 70%, from about 1,383 per 1,000 live births to 398 per 1,000. The average time per screen dropped from roughly 12.5 minutes for a blood test to under 3 minutes for a TcB measurement. Per-screen costs were dramatically lower: about $3.50 for a TcB reading versus $16 in hospital and up to $65 for a blood draw in a rural community setting. Over six months, one hospital program saved nearly $20,000.24PubMed Central. Cost savings with transcutaneous screening versus total serum bilirubin measurement for newborn jaundice in hospital and community settings: a cost-minimization analysis Those savings come not just from cheaper supplies but from reduced nursing time and fewer laboratory processing steps.
Early Detection of Pathological Jaundice
Most newborn jaundice is physiological and harmless, but a small number of babies develop pathological hyperbilirubinemia from conditions like ABO blood-group incompatibility between mother and baby. TcB can flag these cases early. One study found that when a baby’s TcB level was at or above about 5.7 mg/dL (98 µmol/L) at just six hours of age, ABO hemolytic disease could be detected with 100% sensitivity and 98% specificity.25Medicina. The value of transcutaneous method of bilirubin measurement in newborn population with the risk of ABO hemolytic disease Sensitivity and specificity declined as the baby got older, which makes sense because the natural rise in bilirubin in all newborns creates more overlap between healthy and affected babies. The finding highlights a potential role for very early TcB checks in at-risk populations, where catching hemolytic disease in the first hours can change the treatment plan.
Smartphone-Based Bilirubin Screening
Researchers have been exploring whether a smartphone camera could estimate bilirubin from a photo of the baby’s skin, which would make screening accessible in resource-limited settings without any specialized device. An early proof-of-concept app called BiliCam used digital image analysis to estimate bilirubin levels from photos taken under controlled conditions.26PubMed Central. Use of a Smartphone App to Assess Neonatal Jaundice The technology is still in its early stages and faces the same challenges as hardware-based TcB devices: variations in ambient lighting, skin pigmentation, and camera hardware all introduce noise. But the appeal is obvious. In parts of the world where jaundice-related brain injury still occurs because babies are discharged without any bilirubin check, a phone-based screen could fill a critical gap. Whether these apps will reach the reliability needed for clinical decisions remains an open question, but development is active and the concept aligns with the broader shift toward low-cost, point-of-care diagnostics in neonatal care.